Ian Steward
Family · Kalamazoo, MINPI 1235105016
Payments from drug & device makers
Across 375 payments — averaging $15.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$2K
- AbbVie$580
- Novo Nordisk$326
- Otsuka America Pharmaceutical, Inc.$307
- Pfizer$302
- AstraZeneca$252
- plus $3K from 34 others
What the payments were for
- Food & beverage$5,58895%
- Education$3075%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 127 | $1,551 |
| AbbVie | 38 | $580 |
| Novo Nordisk | 26 | $326 |
| Otsuka America Pharmaceutical, Inc. | 14 | $307 |
| Pfizer | 16 | $302 |
| AstraZeneca(2 entities) | 17 | $252 |
| Astellas Pharma US Inc | 4 | $230 |
| Johnson & Johnson | 15 | $219 |
| Lundbeck LLC | 8 | $193 |
| Axsome Therapeutics, Inc. | 8 | $189 |
| Amgen | 11 | $188 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $179 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $132 |
| Bayer | 7 | $113 |
| Merck | 7 | $104 |
| Boehringer Ingelheim | 5 | $91 |
| Lilly USA, LLC | 6 | $81 |
| Almatica Pharma LLC | 4 | $77 |
| Eisai Inc. | 4 | $75 |
| Nestle Healthcare Nutrition Inc. | 4 | $68 |
| Xeris Pharmaceuticals, Inc. | 3 | $66 |
| Teva Pharmaceuticals USA, Inc. | 4 | $64 |
| Alnylam Pharmaceuticals Inc. | 4 | $63 |
| Exact Sciences | 3 | $43 |
| Idorsia Pharmaceuticals US Inc | 2 | $40 |
| Abbott | 2 | $38 |
| Aimmune Therapeutics, Inc. | 2 | $35 |
| Vanda Pharmaceuticals Inc. | 2 | $33 |
| Phathom Pharmaceuticals, Inc. | 2 | $31 |
| Novartis | 2 | $30 |
| GSK | 2 | $28 |
| Alkermes, Inc. | 1 | $26 |
| Mylan Specialty L.p. | 1 | $25 |
| Sunovion Pharmaceuticals Inc. | 2 | $22 |
| Amarin Pharma, Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Phadia US Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Genentech USA, Inc. | 1 | $12 |
How this compares
$5,894 in reported general payments places this provider in the 95th percentile of 3,657 family providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 174 | $119,526 |
| OzempicSemaglutide | 90 | $105,742 |
| FarxigaDapagliflozin Propanediol | 114 | $100,602 |
| TrulicityDulaglutide | 71 | $98,463 |
| EliquisApixaban | 81 | $87,683 |
| MounjaroTirzepatide | 70 | $86,522 |
| VraylarCariprazine Hcl | 32 | $50,429 |
| JardianceEmpagliflozin | 60 | $48,142 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $44,516 |
| ZenpepLipase/Protease/Amylase | 18 | $41,854 |
| JanuviaSitagliptin Phosphate | 41 | $41,271 |
| CreonLipase/Protease/Amylase | 17 | $37,976 |
| MyrbetriqMirabegron | 30 | $28,768 |
| XareltoRivaroxaban | 29 | $26,475 |
| Xigduo XrDapaglifloz Propaned/Metformin | 24 | $25,942 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $81 | $184,985141 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $28 | $144,428227 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $252 | $134,649177 claims |
| Novo NordiskOzempic | $326 | $105,74290 claims |
| AbbVieVraylar, Creon | $580 | $88,40449 claims |
| PfizerEliquis | $302 | $87,68381 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $91 | $57,54278 claims |
| Aimmune Therapeutics, Inc.Zenpep | $35 | $41,85418 claims |
| MerckJanuvia | $104 | $41,27141 claims |
| Astellas Pharma US IncMyrbetriq | $230 | $28,76830 claims |
| Johnson & JohnsonXarelto | $219 | $26,47529 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $179 | $19,62012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,657 family providers in Michigan.
Other family in Kalamazoo
- Jayme HeimGrandville$663K
- Susan WolgamottBloomfield Township$327K
- Elisheva EllenbergDetroit$150K
- Sarah JohnsonFarmington Hills$119K
- Daniela MaximTroy$112K
- Kelsey PrinceGrand Rapids$87K
- Brent MillerFremont$66K
- Rachael CompeauFlint$62K
- David KocendaLapeer$49K
- Tracy RobertsonBay City$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.